Patrick Campbell

The approval indicates Novartis's atrasentan (Vanrafia) for proteinuria reduction in primary IgA nephropathy.

Our Q1 2025 recap for endocrinology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in diabetes care.

Despite failing to achieve significance for its primary endpoint, investigators suggest the trial further demonstrates the potential of cell therapy in HFrEF.

Phase 2 data at ACC.25 provide further insight into the effects of lepodisiran on serum Lp(a) and other biomarkers of risk.

FARES-II trial shows 4-factor PCC is safer, reduces bleeding, transfusions, and complications vs frozen plasma in cardiac surgery.

Data from the REVERSE-IT trial provide vital insight into the efficacy and safety of bentracimab as an FDA decision looms on the horizon.

The WARRIOR trial provides insight into intensive medical therapy in women with INOCA, but investigators caution limitations hinder the applicability of results.

Data from STRIDE at ACC.25 demonstrate semaglutide could provide even greater benefits in type 2 diabetes than previously known.

Announced on March 28, 2025, the FDA's CRL to Milestone Pharmaceuticals cites CMC issues, but no issues with safety or efficacy data.

The FDA approval of diazoxide choline extended-release tablets (Vykat XR) was announced on March 26, 2025.

The March 2025 approval for iptacopan marks the first for C3 glomerulopathy and is based on the APPEAR-C3G trial.

The approval for moderately to severely active Crohn disease marks the fourth indication for Johnson and Johnson's IL-23 inhibitor.

A recap of the 7 phase 3 trials presented during the 2025 AAD annual meeting's late-breaking sessions.

An analysis of data from the DELTA program at AAD 2025 sheds light on the efficacy of delgocitinib for chronic hand eczema.

Data at AAD 2025 and an announcement from Amgen provide insight into the potential role of rocatinlimab in atopic dermatitis.

New data from AAD 2025 and topline results from the ICONIC program underline the potential of icotrokinra in moderate to severe plaque psoriasis.

LIBERTY-BP ADEPT provides further insight into the potential of dupilumab in bullous pemphigoid ahead of the June 2025 PDUFA date.

Phase 3 data from ruxolitinib cream 1.5% presented at AAD 2025 demonstrate the potential of the topical agent in prurigo nodularis.

David Rosmarin, MD, discusses results from ADORING 3 presented at AAD 2025.

New 3-year data from ADjoin demonstrate the efficacy and safety profile of lebrikizumab in moderate to severe atopic dermatitis.

Interim phase 2 data suggest bimiralisib could help patients with actinic keratosis achieve complete or partial clearance of lesions in as little as 2 weeks.

Combined analysis of data from a pair of post-registrational studies demonstrate the clinical profile and patient opinion on treatment with tirbanulin.

The FDA approval for epinephrine nasal spray 1 mg is indicated for type 1 allergic reactions in children 15 to 30 kg and 4 years or older.

The nephrology month in review spotlights HCPLive’s coverage of renal trial developments, xenotransplant, new AKI guidance, and research about dialysis.

A preview of 5 phase 3 clinical trials being presented during the AAD 2025 annual meeting's late-breaking sessions.

John Barbieri, MD, MBA, discusses recent data examining factors associated with formation of benzene in OTC benzoyl peroxide products.

Our top 5 headlines include an FDA approval, a pair of submissions, data from AAAAI 2025, and more!

New data from the REDUCE-IT trial suggests icosapent ethyl offers benefit even among those with LDL-C less than 55 mg/dL.

On Feb. 26, 2025, Arcutis Biotherapeutics announced the FDA's acceptance of their sNDA for roflumilast cream 0.05% in AD for children aged 2 to 5 years.